@article{6e69d3f390d34957be365c75073f7284,
title = "Anti-inflammatory effect of biologic therapy in patients with psoriatic disease: A prospective cohort FDG PET study",
abstract = "Aim: The aim of the study was to evaluate the changes in central vascular inflammation measured by FDG PET and myocardial blood flow reserve (MFR) determined by 82Rb PET following therapy with biologic agents for 6 months in patients with psoriatic arthritis (PsA) and/or cutaneous psoriasis (PsO) (group 1) and compare with PsO subjects receiving non-biologic therapy (group 2) and controls (group 3). Methods and Results: Target-to-background ratio (TBR) by FDG PET in the most diseased segment of the ascending aorta (TBRmax) was measured to assess vascular inflammation. 82Rb PET studies were used to assess changes in left ventricular MFR. A total of 34 participants were enrolled in the study (11 in group 1, 13 in group 2, and 10 controls). A significant drop in the thoracic aorta uptake was observed in the biologic-treated group (ΔTBRmax: − .46 ±.55) compared to the PsO group treated with non-biologic therapy (ΔTBRmax:.23 ±.67). Those showing response to biologic agents maintained MFR compared to who showed no response. Conclusion: In a cohort of psoriasis patients treated with biologics, FDG uptake in the thoracic aorta decreased over the study period. Patients who demonstrated a significant anti-inflammatory response on FDG PET imaging maintained their MFR compared to non-responders.",
keywords = "cardiovascular disease, inflammation, PET imaging, Psoriatic arthritis",
author = "Boczar, {Kevin E.} and Beanlands, {Rob S.} and Glassman, {Steven J.} and Jerry Wang and Wanzhen Zeng and deKemp, {Robert A.} and Ward, {Natalie C.} and Fehlmann, {Christophe A.} and Wells, {George A.} and Jacob Karsh and Girish Dwivedi",
note = "Funding Information: JW, WZ, JK, CAF, NCW, and SG have nothing to disclose. KEB is supported by a CIHR Fellowship Award. RdK reports grants, consulting fees, and license revenues from Jubilant DraxImage and uOttawa Heart Institute (UOHI), outside the submitted work. RSB reports grants and honoraria from Lantheus Medical Imaging, grants and honoraria from Jubilant DraxImage, and grants from GE Healthcare, outside the submitted work. RSB is UOHIs Vered Chair in Cardiology and uOttawa{\textquoteright}s Distinguished Chair in CV Imaging Research. GD is Wesfarmers Chair in Cardiology at University of Western Australia with an Adjunct Professor appointment at UOHI. He has received honoraria from Amgen, Pfizer, and Artrya Ltd and has an equity interest in Artrya Pty Ltd, all outside the submitted work. The study was performed at UOHI. Funding Information: Funding This study was supported by the Canadian Institutes of Health Research (CIHR) grant. KEB is supported by a CIHR Fellowship Award. RSBB was a Career Investigator supported by the Heart and Stroke Foundation of Ontario, the UOHI Vered Chair of Cardiology, and a University of Ottawa Distinguished Chair of Cardiovascular Imaging Research. GD was supported by a CIHR new investigator salary support award (supported by OHTN) while at UOHI. Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
month = aug,
doi = "10.1007/s12350-023-03204-8",
language = "English",
volume = "30",
pages = "1642--1652",
journal = "Journal of Nuclear Cardiology",
issn = "1071-3581",
publisher = "Springer",
number = "4",
}
